Passive immunization with a human monoclonal antibody protects hu-PBL- SCID mice against challenge by primary isolates of HIV-1

Nature Medicine

Volumn 3, Issue 12, 1997, Pages 1389-1393

  Gauduin, Marie Claire ^a,c   Parren, Paul W H I ^b   Weir, Raymond ^a   Barbas, Carlos F ^b   Burton, Dennis R ^b   Koup, Richard A ^a,d,e  

^a ROCKEFELLER UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e Pediatric AIDS Foundation

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; COMBINED IMMUNODEFICIENCY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, SCID; MONOCYTES; NEUTRALIZATION TESTS; TIME FACTORS; TRANSPLANTATION CHIMERA;

EID: 0031449456     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1297-1389     Document Type: Article

References (46)

1. Haynes, B.F. HIV vaccines: Where we are and where we are going. Lancet 348, 933-937 (1996).
2. Burton, D.R. & Montefiori, D.C. The antibody response in HIV-1 infection. AIDS 11 (Suppl. A), S87-S98 (1997).
3. Conley, A.J. et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70, 6751-6758 (1996).
4. Mosier, D.E. et al. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251, 791-794 (1991).
5. Girard, M., Barré-Sinoussi, F., van der Ryst, L. & Fultz, P. Vaccination of chimpanzees against HIV-1. Antibiot. Chemother. 48, 121-124 (1996).
6. Emini, E.A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
7. Cohen, J. Jitters jeopardize AIDS vaccine trials. Science 262, 980-981 (1993).
8. Mascola, J.R. et al. Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype. J. Infect. Dis. 169, 48-54 (1994).
9. Matthews, T.J. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retroviruses 10, 631-632 (1994).
10. Moore, J.P. & Ho, D.D. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS 9 (Suppl. A), S117-S136 (1995).
11. Koup, R.A., Safrit, J.T., Weir, R. & Gauduin, M.C. Defining antibody protection against HIV-1 transmission in HU-PBL-SCID mice. Semin. Immunol. 8, 263-268 (1996).
12. Safrit, J.T. et al. Hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp1 20. AIDS 7, 15-21 (1993).
13. Gauduin, M.C., Safrit, J.T., Weir, R., Fung, M.S. & Koup, R.A. Pre- and post exposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J. Infect. Dis. 171, 1203-1209 (1995).
14. Parren, P.W.H.I. et al. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9, F1-F6 (1995).
15. Burton, D.R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
16. Gauduin, M.C. et al. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma HIV-1 by recombinant immunoglobulin molecules. J. Virol. 70, 2586-2592 (1996).
17. Zuckier, L.S., Rodriguez, L.D. & Scharft, M.D. Immunologic and pharmacologic concepts of monoclonal antibodies. Seminars in Nuclear Medicine 19, 166-186 (1989).
18. Trkola, A. et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69, 6609-6617 (1995).
19. Koyanagi, Y. et al. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236, 819-822 (1987).
20. Koup, R.A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
21. White-Scharf, M.E. et al. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virol. 192, 197-206 (1993).
22. Prince, A.M. et al. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc. Natl. Acad. Sci. USA 85, 6944-6948 (1988).
23. Lambert, J.S. et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. J. Infect. Dis. 175, 283-291 (1997).
24. Cummins, L.M. et al. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 77, 1111-1117 (1991).
25. Trkola, A. et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384, 184-187 (1996).
26. Klasse, P.J. & Moore, J.P. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70, 3668-3677 (1996).
27. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
28. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
29. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586 (1996).
30. Zolla-Pazner, S. & Sharpe, S. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retroviruses 11, 1449-1457 (1995).
31. Burton, D.R. A vaccine for HIV type 1: The antibody perspective. Proc. Natl. Acad. Sci. USA 94, 10018-10023 (1997).
32. Kessler, J.A. et al. The recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retroviruses 13, 575-582 (1997).
33. Burton, D.R. et al. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134-10137 (1991).
34. Roben, P. et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68, 4821-4828 (1994).
35. D'Souza, M.P. et al. Evaluation of monoclonal antibodies to HIV-1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175, 1056-1062 (1997).
36. Allaway, G.P. et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11, 533-539 (1995).
37. Mosier, D.E., Gulizia, R.J., Baird, S.M. & Wilson, D.B. Transfer of functional human immune system in mice with severe combined immunodeficiency. Nature 355, 728-730 (1988).
38. Hesselton, R.M. et al. Human peripheral blood xenografts in the SCID mouse: Characterization of immunologic reconstitution. J. Infect. Dis. 168, 630-640 (1993).
39. Ho, D.D., Moudgil, T. & Alam, M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321, 1621-1625 (1989).
40. Koup, R.A. & Ho, D.D. Quantitative culture assay for HIV-1 in peripheral blood. in Techniques in HIV Research (eds. Aldovini, A. & Walker, B.D.) 107-112 (Stockton, New York, 1994).
41. Barré-Sinoussi, F. et al. Isolation of a T-lymphocyte retrovirus from patient at risk for acquired immunodeficiency syndrome (AIDS). Science 220, 868-871 (1983).
42. Moore, J.P., Cao, Y., Ho, D.D. & Koup, R.A. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 68, 5142-5155 (1994).
43. Ho, D.D. et al. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88, 8949-8952 (1991).
44. Ho, D.D. et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65, 489-493 (1991).
45. Ho, D.D. et al. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol. 61, 2024-2028 (1987).
46. Koup, R.A., Hesselton, R.M., Safrit, J.T., Somasundran, M. & Sullivan, J.L. Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acute-infected Hu-PBL-SCID mice. AIDS Res. Hum. Retroviruses 10, 279-284 (1994).